Batch-linked records

Documentation Status

SELECT A STRENGTH
Selected strength
Not selected
Batch
Pending selection
Laboratory
Published with report
Analysis date
Published with report
View laboratory details

LaboratoryPublished with report

Select a labeled strength to confirm whether released batch documentation is available.

CJC + IPA

Price range: $70.00 through $100.00

CJC + IPA research material offered in selectable labeled strengths: 5 MG + 5 MG and 10 MG + 10 MG. Batch-specific analytical documentation is displayed only after review and release. For laboratory research use only.

For laboratory research use only Not for human or veterinary use. Review batch documentation before ordering.

Description

CJC + IPA | Product Description

CJC + IPA | Introduction

CJC + IPA is cataloged here under the following research classification: Two-component catalog material labeled CJC + IPA. This catalog material is offered strictly for controlled laboratory research. It is not intended for diagnostic, therapeutic, human, or veterinary use.

Documentation hold: Exact CJC variant, component forms, and constituent identity require product-specific verification. Public molecule-level claims will remain limited until that record is verified.

  • Dual-component identity testing
  • Comparative receptor-pathway models
  • Analytical separation and quantitation

At a glance: Two-component catalog material labeled CJC + IPA · 5 MG + 5 MG and 10 MG + 10 MG · Batch-specific documentation

CJC + IPA | Molecular Identity & Composition
Material name CJC + IPA
Research classification Two-component catalog material labeled CJC + IPA
Research context GHRH-receptor and ghrelin-receptor research systems, subject to constituent verification
Labeled quantity 10/10 mg
SKU NTR-CJCIPA-10-10MG
Identity control Exact CJC variant, component forms, and constituent identity require product-specific verification.
Physical form and storage Confirm against the specific batch record and packaging before handling
Purity and identity Batch-specific results only; review the Third-Party COA tab when an approved record is available
CJC + IPA | Available Strengths

Select the labeled strength required for the approved laboratory protocol:

  • 5 MG + 5 MG
  • 10 MG + 10 MG

Each strength retains its own inventory stage and batch-documentation relationship.

Ntegrity Quality & Documentation

Ntegrity Labs treats analytical evidence as batch-specific. A product-level statement does not replace the underlying laboratory report. When approved documentation is available, the testing tab identifies the relevant material, batch, laboratory, methods, test date, and reported results.

  • No purity claim is applied across unrelated batches.
  • Third-party and group-buy reports retain their original laboratory and customer provenance.
  • A report is published only after its product and batch relationship has been reviewed.
Category Overview | Multi-Component Endocrine Signaling Research Materials

This category includes catalog materials containing more than one research component. Constituent identity, proportion, and batch documentation must be verified before molecule-level claims are released.

Category placement describes research context only. It is not a statement of clinical performance, safety, or intended therapeutic use.

CJC + IPA | Research Context & Applications

Published studies describe CJC-1295 as a long-acting GHRH analogue and ipamorelin as a ghrelin-receptor agonist. This catalog label does not by itself verify the CJC variant, component form, or analytical identity. Product-specific documentation takes precedence.

Published studies describe the referenced research molecule or catalog context. They do not verify the identity of an untested batch or establish an intended use for the Ntegrity Labs material on this page.

Research Use Disclaimer

This material is intended exclusively for laboratory research and analytical work. It is not for human or veterinary use and is not intended for diagnosis, treatment, cure, mitigation, or prevention of disease. Purchasers are responsible for lawful acquisition, qualified handling, appropriate storage, and use within suitable research facilities.

CJC + IPA batch and COA registry

Use this page to verify the labeled strength, batch or lot identifier, testing laboratory, and current third-party report before ordering or beginning laboratory work.

StrengthStatusBatch / lotTest dateLaboratoryResultsReport
5 MG + 5 MG Current AUC-CP10 2026-02-25 Janoshik Analytical Identity confirmed; see full report View COA
10 MG + 10 MGIn ProductionNo released batch or COA is published for this strength.